Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

On a single Tuesday in July, two pharmaceutical companies that already dominate American medicine cabinets squared off in a federal courtroom. Novo Nordisk, the Danish maker of Wegovy and Ozempic, filed a false-advertising lawsuit against Eli Lilly, the Indianapolis maker of Zepbound and Mounjaro, accusing its American rival of building a nationwide ad campaign on apples-to-oranges dosing comparisons. ³⁵⁸¹⁰

The complaint, filed July 21, 2026 in the U.S. District Court for the District of New Jersey under the caption Novo Nordisk Inc. v. Eli Lilly and Co., lands at the intersection of two of the most prescribed drug franchises in the country. ¹⁰⁵⁸ On one side stand Wegovy, approved for weight loss, and Ozempic, approved for type 2 diabetes. On the other, Lilly's Zepbound for weight loss and Mounjaro for diabetes. Together, those four brand names have reshaped how American physicians treat obesity and metabolic disease, and they now anchor one of the most lucrative therapeutic categories in modern pharmaceuticals.

Novo's central allegation is comparatively narrow, and that is what makes it combustible. The company says Lilly's direct-to-consumer campaigns pair the highest approved doses of Mounjaro and Zepbound against lower doses of Wegovy and Ozempic, while leaving out Novo's newer, higher-dose formulations that compete more directly with the top of Lilly's range. The effect, Novo argues, is a misleading impression of head-to-head superiority built on what the company calls "outdated" clinical trial data. ²⁴⁹¹⁰

The suit is not framed as a fight over scientific truth in the abstract. It is a request for a federal injunction. Novo is asking the court to order Lilly to pull the comparative advertising and to stop running what the complaint characterizes as a "nationwide pattern of deceptive advertising." ⁹¹¹ The company alleges violations of federal and state false-advertising and unfair-competition law, and frames the campaign as deliberately simple and, in its telling, deliberately false. ⁵ CBS News, reporting on the filing, went further, characterizing the suit as alleging the ads were "maliciously and deceptively false." ⁶

Novo's own press release, timed to the filing, argued that Lilly's materials "confuse consumers by using outdated studies to compare the highest injectable doses of Lilly's medicines against lower doses of Novo Nordisk's injectable medicines for obesity and type 2 diabetes." ⁹ The legal filing is the more aggressive version of a complaint that has surfaced for months in industry trade press: that Lilly's marketing was not merely confident, but structurally tilted.

Lilly's public posture, in the hours after the filing, was to defend the advertisements as truthful, accurate, and grounded in the best available scientific evidence and clinical data. The company says the dosing comparisons at issue are supported by head-to-head data, not by inference. The research file does not contain a verbatim Lilly statement for citation; the response summarized here tracks Lilly's public line as it was reported the day of the suit, but the precise words cannot be placed in quotation marks on the record available.

That gap matters. The legal fight will turn on which side the court credits, and on whether a judge sees the comparison as fair scientific context or as a marketing device that hides the existence of a higher-dose Novo rival. The way Lilly frames the same studies, and the studies it points to in its own defense, will do as much work as any expert declaration.

GLP-1 drugs, the class that includes all four medicines in the dispute, are dosed on a curve. Patients typically start at low introductory doses and titrate upward as tolerability allows. Efficacy data is reported at the doses actually studied, and the higher the dose, the larger the average weight loss in clinical trials. That is the metric a comparative ad is most tempted to deploy, and it is also the metric most likely to mislead if the comparison does not match the top of each company's range against the top of the other's.

Wegovy's highest approved dose sits at 2.5 mg in maintenance, with Novo's newer higher-dose Wegovy formulation pitched as the more direct competitor to Lilly's top of the range. Zepbound, the Lilly rival, runs up to 15 mg at its highest approved maintenance dose. ²¹⁰ The complaint's claim is that Lilly's campaign used the top of its own dose-response curve and the middle of Novo's, then presented the result as a head-to-head. Novo argues that doing so quietly buries the newer Novo formulations that would have been the fairer matchup. ²⁹¹⁰

Neither company's filing puts a dollar figure on the GLP-1 category as a whole. The HeyDay video narration cited a roughly $150 billion market for the drug class, a number that has circulated in industry coverage in recent quarters, but that figure does not appear in any of the source documents used to prepare this article and should be treated as a widely reported estimate rather than a confirmed tally. What is documented is the scale of the four-drug rivalry: Wegovy, Ozempic, Zepbound and Mounjaro are the names that, together, have moved GLP-1 treatment from a niche endocrinology prescription into a mainstream primary-care conversation. ²³⁴

The suit is a fight between two incumbents, not a David-and-Goliath story, and that is part of why it is worth watching. The four drugs at its center already shape how tens of millions of Americans understand weight loss and diabetes treatment, and the ad campaigns around them are a primary source of that understanding. If a federal court accepts Novo's framing, comparative GLP-1 advertising across the category will have to match doses honestly across the top of each company's range. If the court sides with Lilly, the more aggressive form of comparative marketing that Novo is challenging will have a judicial stamp. Either way, the courtroom, not the copywriter, will end up drawing the line.